Scholler N - Search Results

1

Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/Mesothelin-dependent cell attachment.

Bergan L, Gross JA, Nevin B, Urban N, Scholler N. Bergan L, et al. Among authors: scholler n. Cancer Lett. 2007 Oct 8;255(2):263-74. doi: 10.1016/j.canlet.2007.04.012. Epub 2007 Jun 7. Cancer Lett. 2007. PMID: 17560019

2

Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma.

Brudno JN, Lam N, Vanasse D, Shen YW, Rose JJ, Rossi J, Xue A, Bot A, Scholler N, Mikkilineni L, Roschewski M, Dean R, Cachau R, Youkharibache P, Patel R, Hansen B, Stroncek DF, Rosenberg SA, Gress RE, Kochenderfer JN. Brudno JN, et al. Among authors: scholler n. Nat Med. 2020 Feb;26(2):270-280. doi: 10.1038/s41591-019-0737-3. Epub 2020 Jan 20. Nat Med. 2020. PMID: 31959992 Free PMC article. Clinical Trial.

3

Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma.

Scholler N, Fu N, Yang Y, Ye Z, Goodman GE, Hellström KE, Hellström I. Scholler N, et al. Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11531-6. doi: 10.1073/pnas.96.20.11531. Proc Natl Acad Sci U S A. 1999. PMID: 10500211 Free PMC article.

4

Plasmid-based vaccines encoding rat neu and immune stimulatory molecules can elicit rat neu-specific immunity.

Disis ML, Scholler N, Dahlin A, Pullman J, Knutson KL, Hellström KE, Hellström I. Disis ML, et al. Among authors: scholler n. Mol Cancer Ther. 2003 Oct;2(10):995-1002. Mol Cancer Ther. 2003. PMID: 14578464

5

Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma.

McIntosh MW, Drescher C, Karlan B, Scholler N, Urban N, Hellstrom KE, Hellstrom I. McIntosh MW, et al. Among authors: scholler n. Gynecol Oncol. 2004 Oct;95(1):9-15. doi: 10.1016/j.ygyno.2004.07.039. Gynecol Oncol. 2004. PMID: 15385104 Free PMC article.

6

Bead-based ELISA for validation of ovarian cancer early detection markers.

Scholler N, Crawford M, Sato A, Drescher CW, O'Briant KC, Kiviat N, Anderson GL, Urban N. Scholler N, et al. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2117-24. doi: 10.1158/1078-0432.CCR-05-2007. Clin Cancer Res. 2006. PMID: 16609024 Free PMC article.

7

Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery.

Scholler N, Garvik B, Hayden-Ledbetter M, Kline T, Urban N. Scholler N, et al. Cancer Lett. 2007 Mar 8;247(1):130-6. doi: 10.1016/j.canlet.2006.03.029. Epub 2006 May 4. Cancer Lett. 2007. PMID: 16677756 Free PMC article.

8

Method for generation of in vivo biotinylated recombinant antibodies by yeast mating.

Scholler N, Garvik B, Quarles T, Jiang S, Urban N. Scholler N, et al. J Immunol Methods. 2006 Dec 20;317(1-2):132-43. doi: 10.1016/j.jim.2006.10.003. Epub 2006 Oct 30. J Immunol Methods. 2006. PMID: 17113097 Free PMC article.

9

Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA.

Scholler N, Lowe KA, Bergan LA, Kampani AV, Ng V, Forrest RM, Thorpe JD, Gross JA, Garvik BM, Drapkin R, Anderson GL, Urban N. Scholler N, et al. Clin Cancer Res. 2008 May 1;14(9):2647-55. doi: 10.1158/1078-0432.CCR-07-1442. Clin Cancer Res. 2008. PMID: 18451228 Free PMC article.

10

Combining a symptoms index with CA 125 to improve detection of ovarian cancer.

Andersen MR, Goff BA, Lowe KA, Scholler N, Bergan L, Dresher CW, Paley P, Urban N. Andersen MR, et al. Among authors: scholler n. Cancer. 2008 Aug 1;113(3):484-9. doi: 10.1002/cncr.23577. Cancer. 2008. PMID: 18615684 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results